Limitations in efficacy of antidepressant monotherapy

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 10, 2007, Pages 8-10

  Rush, A John ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; LIOTHYRONINE; LITHIUM; LITHIUM CARBONATE; MIRTAZAPINE; NORTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SUICIDE ATTEMPT; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34848887987     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Farvolden P, Kennedy SH, Lam RW. Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs 2003;12:65-86
3. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-153
4. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-204
5. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142
6. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007;164:753-760
7. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Res 2005;7:441-446
8. Schweiger U, Weber B, Deuschle M, et al. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psychiatry 2000;157:118-120
9. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006;59:493-501
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
11. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion SR, sertraline, or venlafaxine XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
12. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
13. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172
14. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541